In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews (11/03)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, The New Movement in Spine, features profiles of Archus Orthopedics Inc., AxioMed Spine Corp., Gelifex Inc. and Replication Medical Inc. Plus these Start-Ups Across Health Care: Advanced Circulatory Systems Inc., Ambrx Inc., Clearant Inc., Compound Therapeutics Inc., Hydra Biosciences Inc., NanoBio Corp., Phenomix Corp. and VisEn Medical Inc.

You may also be interested in...



What’s Next? Five Things To Look Out For In April

Generics Bulletin previews the biggest events and changes for industry in the coming month.

Keeping Track: More Rx-To-OTC Switches On Deck After US FDA’s OTC Narcan Approval; Iovance Looks To Bring Cell Therapy To Melanoma

The latest drug development news and highlights form the Pink Sheet’s US FDA Performance Tracker.

Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases

EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel